1. Home
  2. MGX vs ATPC Comparison

MGX vs ATPC Comparison

Compare MGX & ATPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGX
  • ATPC
  • Stock Information
  • Founded
  • MGX 2018
  • ATPC 2016
  • Country
  • MGX United States
  • ATPC Malaysia
  • Employees
  • MGX N/A
  • ATPC N/A
  • Industry
  • MGX
  • ATPC Medical/Nursing Services
  • Sector
  • MGX
  • ATPC Health Care
  • Exchange
  • MGX NYSE
  • ATPC Nasdaq
  • Market Cap
  • MGX 62.1M
  • ATPC 68.0M
  • IPO Year
  • MGX 2024
  • ATPC N/A
  • Fundamental
  • Price
  • MGX $2.17
  • ATPC $1.47
  • Analyst Decision
  • MGX Strong Buy
  • ATPC
  • Analyst Count
  • MGX 4
  • ATPC 0
  • Target Price
  • MGX $13.00
  • ATPC N/A
  • AVG Volume (30 Days)
  • MGX 912.4K
  • ATPC 55.8K
  • Earning Date
  • MGX 08-13-2025
  • ATPC 08-13-2025
  • Dividend Yield
  • MGX N/A
  • ATPC N/A
  • EPS Growth
  • MGX N/A
  • ATPC N/A
  • EPS
  • MGX N/A
  • ATPC N/A
  • Revenue
  • MGX $45,263,000.00
  • ATPC $1,293,141.00
  • Revenue This Year
  • MGX N/A
  • ATPC N/A
  • Revenue Next Year
  • MGX $11.75
  • ATPC N/A
  • P/E Ratio
  • MGX N/A
  • ATPC N/A
  • Revenue Growth
  • MGX N/A
  • ATPC N/A
  • 52 Week Low
  • MGX $1.23
  • ATPC $0.90
  • 52 Week High
  • MGX $5.50
  • ATPC $6.80
  • Technical
  • Relative Strength Index (RSI)
  • MGX 71.83
  • ATPC 45.37
  • Support Level
  • MGX $1.45
  • ATPC $1.37
  • Resistance Level
  • MGX $2.47
  • ATPC $1.47
  • Average True Range (ATR)
  • MGX 0.16
  • ATPC 0.09
  • MACD
  • MGX 0.09
  • ATPC 0.02
  • Stochastic Oscillator
  • MGX 75.47
  • ATPC 47.48

About MGX METAGENOMI INC

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

About ATPC Agape ATP Corporation

Agape ATP Corp through its subsidiaries is engaged in providing health and wellness products and health solution advisory services. The principal activities of the company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs. Its segments include: Skin care, health and wellness segment includes the provision of health and wellness products and health solution advisory services; and Green energy segment includes providing renewable energy products, technical solutions, installations and maintenance services. It derives maximum revenue from Skin care, health and wellness segment.

Share on Social Networks: